Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Introduction: Several reports have shown marked heterogeneity of antibiotic pharmacokinetics (PK) in patients admitted to ICUs, which might potentially affect outcomes. Therefore, the pharmacodynamic (PD) parameter of the efficacy of β-lactam antibiotics, that is, the time that its concentration is above the bacteria minimal inhibitory concentration (T > MIC), cannot be safely extrapolated from data derived from the PK of healthy volunteers. Methods: We performed a full review of published studies addressing the PK of intravenous β-lactam antibiotics given to infected ICU patients. Study selection comprised a comprehensive bibliographic search of the PubMed database and bibliographic references in relevant reviews from January 1966 to December 2010. We selected only English-language articles reporting studies addressing β-lactam antibiotics that had been described in at least five previously published studies. Studies of the PK of patients undergoing renal replacement therapy were excluded. Results: A total of 57 studies addressing six different β-lactam antibiotics (meropenem, imipenem, piperacillin, cefpirome, cefepime and ceftazidime) were selected. Significant PK heterogeneity was noted, with a broad, more than twofold variation both of volume of distribution and of drug clearance (Cl). The correlation of antibiotic Cl with creatinine clearance was usually reported. Consequently, in ICU patients, β-lactam antibiotic half-life and T > MIC were virtually unpredictable, especially in those patients with normal renal function. A better PD profile was usually obtained by prolonged or even continuous infusion. Tissue penetration was also found to be compromised in critically ill patients with septic shock. Conclusions: The PK of β-lactam antibiotics are heterogeneous and largely unpredictable in ICU patients. Consequently, the dosing of antibiotics should be supported by PK concepts, including data derived from studies of the PK of ICU patients and therapeutic drug monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Heterogeneity of volume of distribution in litres of β-lactam antibiotics in ICU patients. Open circles: volume of distribution in healthy volunteers [44,51,89-92]; filled squares: weighted means of volume of distribution in the studies; straight lines: ranges of the means of volume of distribution in the studies.](https://figures.cochat.ai/paper-figures/83611cc812e44433b6b33a2cd391c970/antibiotics-in-critically-ill-patients-a-systematic-review-of-the-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beta-lactam antibiotics may be subject to changes in important pharmacokinetic parameters in the setting of sepsis and septic shock resulting in sub-therapeutic concentrations [230, 231].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [230]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Basic & Clinical Biostatistics
Dawson, B. K., & Trapp, R. G. (2004) · Cited by 699
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556 · cited 1×
“Considerable evidence demonstrates that free drug time above bacteria minimal inhibitory concentration (f T > MIC) is the measure of drug exposure most closely linked to the ability of b-lactam antibiotics to kill the target bacteria [4].”
BackgroundThe epidemiology of the systemic inflammatory response
Brun-Buisson, C. (2000) · Intensive Care Medicine · doi:10.1007/s001340051121 · Cited by 534 · cited 1×
“Infection and sepsis, whether community- or hospitalacquired, are important causes of morbidity and mortality in ICU patients [1,2].”
BackgroundFridkin, S. K., Steward, C. D., Edwards, J. R., Pryor, E. R., McGowan, Jr., Archibald, L. K., Gaynes, R. P., & Tenover, F. C. (1999) · Clinical Infectious Diseases · doi:10.1086/520193 · Cited by 486
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
Taccone, F. S., Laterre, P.-F., Dugernier, T., Spapen, H., Delattre, I., Wittebole, X., De Backer, D., Layeux, B., Wallemacq, P., Vincent, J.-L., et al. (2010) · Critical Care · doi:10.1186/cc9091 · Cited by 369 · cited 2×
“…= 8 mg/L: bolus 70%, CI 100% CFR for EC: bolus 100%, CI 100% CFR for PA: bolus 40.6%, CI 100% Ceftazidime, 2 g 70% T > 4 × EUCAST breakpoint of PA 28% Taccone et al., 2010 [23] Cefepime, 2 g 70% T > 4 × EUCAST breakpoint of PA 16% Meropenem, 1 g 40% T > 4 × EUCAST breakpoint of PA…”
BackgroundInfluentialRoberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp139 · Cited by 347 · cited 13×
“…± 4.9 6.7 ± 4.2 3.7 ± 1.9 N = 6 Age 65.7 ± 11.2 years Peritonitis Descriptive Karjagin et al., 2008 [25] Meropenem 22.7 13.6 ± 1.3 NR N = 10 Age range 48 to 63 years Severe sepsis Randomized, parallel controlled Roberts et al., 2009 [24] Meropenem Meropenem 30.1 [21.7 to 53.9]e Meropenem 8 [5 to…”
BackgroundMethodInfluentialTherapeutic drug monitoring of β-lactams in critically ill patients: proof of concept
Roberts, J. A., Ulldemolins, M., Roberts, M. S., McWhinney, B., Ungerer, J., Paterson, D. L., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.008 · Cited by 334
Pea, F., Viale, P., & Furlanut, M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00002 · Cited by 327 · cited 1×
“Drugs that distribute essentially in the extracellular fluid (mainly hydrophilic) have low Vd, whilst drugs that have rapid cellular uptake (lipophilic) have high Vd[5,6].”
Background
Cited by
Items 401–409 of 409
Çakır, A., Memiş, H., GÜN, Z. Ü., Demirpolat, E., Duzencı, D., Bıçakcıoğlu, M., & Karakükcü, Ç. (2026) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1770074
Escolà‐Rodríguez, A., Sandoval, E., Rigo-Bonnin, R., Santoyo, A. T., Herrera, S., Meneses, M. H., Carramiñana, A., de Medrano, J. I. S., Serra, M. B., Moisés, J., et al. (2026) · Critical Care · doi:10.1186/s13054-026-06076-9
“Cmax, AUC 0–24 , t 1/2 , CL, and Vd values fell within the ranges described in the literature for ICU patients receiving comparable dosing regimens, including patients with similar clinical characteristics, such as renal impairment or concomitant renal replacement therapy [39–43].”
Fiori, C., Piana, A., Manfredi, M., & Amparore, D. (2026) · Springer eBooks · doi:10.1007/978-3-031-52619-0_7
Shi, S., Cui, J., Liu, G., Gao, J., & Bai, W. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70067
Qiu, B., Huang, J., Zhang, F., & Wang, Y. (2026) · Journal of Chemotherapy · doi:10.1080/1120009x.2026.2684308
Luxton, T., West, R. M., King, N., Gould, R., Wälti, C., & Sandoe, J. A. T. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag230
Maseda, E., Candel, F. J., Navarro, D., Clari, M. Á., Adalia, R., Rico-Feijoó, J., Aguilar, G., Varela, M., Ramasco, F., Aldecoa, C., et al. (2026) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2026.502210
Lei, Z., Liang, H., Cheng, Q., Kong, W., Du, Y., Yao, X., Feng, F., Jin, Y., Wang, W., Li, H., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091113
Giurazza, R., Cosenza, G., Fiore., M., Notaro, S., Sansone, P., Pota, V., Coppolino, F., Piccialli, F., & Pace, M. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197697
Metadata
- Authors
- Gonçalves-Pereira, J., & Póvoa, P.
- Affiliations
- University of Lisbon (PT)
- ORCID
- Póvoa, Pedro
- Venue
- Critical Care
- Published
- 2011-09-13
- Volume
- 15
- Issue
- 5
- Pages
- R206-R206
- ISSN
- 1364-8535 (ISSN-L)
- PMC
- PMC3334750
- OpenAlex
- W2070242840
- Semantic Scholar
- 028a21fcf10a276ab1fc87191ee4ae66b704ce5e
- Cited by
- 408
- References
- 93
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 26 · 2023: 36 · 2022: 32 · 2021: 43 · 2020: 27 · 2019: 22 · 2018: 24 · 2017: 25 · 2016: 27 · 2015: 26 · 2014: 31 · 2013: 17 · 2012: 21
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Critical Care (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- beta-lactam antibiotics, antibiotic pharmacokinetics, critically ill patients, intensive care unit, volume of distribution, drug clearance, creatinine clearance, half-life, time above MIC, pharmacodynamics, continuous infusion, septic shock, tissue penetration, therapeutic drug monitoring, antibiotic dosing, meropenem, imipenem, piperacillin, cefpirome, cefepime, ceftazidime
- MeSH terms
- Cefepime, Meropenem, Cefpirome, Anti-Bacterial Agents, Ceftazidime, Cephalosporins, Humans, Infections, Piperacillin, Thienamycins, Imipenem, Critical Illness, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.